Gaining an Enhanced Understanding of HER2 Expression in Breast Cancer

By Dr. Margaret Gatti-Mays - Last Updated: March 31, 2025

Advancements in Oncology panelist Margaret Gatti-Mays, MD, MPH, continues her post-panel discussion by delving into the topic of HER2 tumor expression. She also details the DESTINY Breast-06 study that was presented at the 2024 American Society of Clinical Oncology Annual Meeting. The study found that patients with HER2-low and HER2-ultra-low expression can benefit from treatment with newer antibody-drug conjugates.

Advertisement

Advertisement